SCHEMBL2035264

SCHEMBL2035264

CC(=O)c1ccnc(N2CCCC2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
GBA1 P04062 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
MAPK8 P45983 1/20 0.45
CDC7 O00311 1/20 0.45
PTGS2 P35354 1/20 0.43
MAPT P10636 1/20 0.43
ACACB O00763 3/20 0.43
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
DYRK1A Q13627 1/20 0.42
ACHE P22303 4/20 0.41
HSD17B10 Q99714 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
CYP2D6 P10635 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28071006 0.98 POLB (0.54) POLBSMN1; SMN2GBA1NPC1RAB9A
SCHEMBL25877128 0.86 PIK3CA (0.48) POLBSMN1; SMN2NPC1RAB9APTGS2
SCHEMBL28070878 0.85 MAPK8 (0.52) POLBSMN1; SMN2GBA1MAPK8CDC7
SCHEMBL9461754 0.83 ALDH1A1 (0.56) POLBSMN1; SMN2GBA1NPC1MAPK8
SCHEMBL28087268 0.83 MAPK8 (0.54) POLBSMN1; SMN2GBA1MAPK8CDC7
SCHEMBL27903086 0.83 GBA1 (0.43) POLBSMN1; SMN2GBA1MAPK8CDC7
SCHEMBL28059117 0.81 CRBN (0.55) POLBSMN1; SMN2GBA1NPC1RAB9A
SCHEMBL27029578 0.80 DKK1 (0.51) POLBNPC1RAB9AALDH1A1KMT2A
SCHEMBL28141516 0.78 MAPK8 (0.44) POLBSMN1; SMN2GBA1MAPK8CDC7
SCHEMBL25237476 0.78 ACHE (0.60) POLBMAPTALDH1A1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2516397-B1 Amino-heteroaryl derivatives as HCN blockers MERCK SHARP & DOHME (NL) 2016-07-13 EP disclosed
US-8952001-B2 Amino-heteroaryl derivatives as HCN blockers MERCK SHARP & DOHME CORP. (US) 2015-02-10 US disclosed
EP-2516397-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS MSD Oss B.V. (NL) 2012-10-31 EP disclosed
US-20120264728-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-10-18 US disclosed
WO-2011076723-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS N.V. ORGANON (NL) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264728-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS HCN1, HCN3, HCN2 POLB 3931/4885SMN1; SMN2 2942/4885GBA1 1083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.